Batiraxcept + Durvalumab

Phase 1/2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Platinum-Resistant Fallopian Tube Carcinoma

Conditions

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma

Trial Timeline

Dec 3, 2019 → Oct 24, 2024

NCT ID

NCT04019288

About Batiraxcept + Durvalumab

Batiraxcept + Durvalumab is a phase 1/2 stage product being developed by AstraZeneca for Platinum-Resistant Fallopian Tube Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04019288. Target conditions include Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04019288	Phase 1/2	Terminated	Dec 3, 2019	Oct 24, 2024	Platinum-Resistant Fallopian Tube Carcinoma

Competing Products

16 competing products in Platinum-Resistant Fallopian Tube Carcinoma

See all competitors

Product	Company	Stage	Hype Score
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cells	Precigen	Phase 1	28
Niraparib + Anlotinib	Sun Pharmaceutical	Phase 2	52
E7050 + Cetuximab	Eisai	Phase 1/2	41
PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd + PLD 40mg/m2 ivgtt q4w	Jiangsu Hengrui Medicine	Phase 2	52
olaparib+cediranib combination therapy + durvalumab + olaparib combination therapy + durvalumab + chemotherapy treatment + durvalumab + tremelimumab + chemotherapy treatment + durvalumab + tremelimumab + paclitaxel treatment + durvalumab +chemotherapy treatment	AstraZeneca	Phase 2	52
Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + Gemcitabine	Merck	Phase 3	77
CRS-207 + Epacadostat + Pembrolizumab	Incyte	Phase 1/2	38
Rina-S + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin (PLD) + Gemcitabine	Genmab	Phase 3	74
Bevacizumab + Irinotecan Sucrosofate	Ipsen	Phase 2	49
Gemcitabine + N-803 + M-CENK	ImmunityBio	Phase 2	49
Drug Product De-TIL-0255	Nurix Therapeutics	Phase 1	28
Pegylated Liposomal Doxorubicin + SL-172154 + Mirvetuximab + SL-172154	Shattuck Labs	Phase 1	25
CTIM-76	Context Therapeutics	Phase 1	25
Lorigerlimab	MacroGenics	Phase 2	44
olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or cisplatin + Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin + Bevacizumab (or biosimilar)	Genelux	Phase 3	69
PHI-101 administration	iBio	Phase 1	25

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved